These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17612904)

  • 1. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
    Ruilope L; Kjeldsen SE; de la Sierra A; Mancia G; Ruggenenti P; Stergiou GS; Bakris GL; Giles TD
    Blood Press; 2007; 16(2):72-9. PubMed ID: 17612904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
    Mancia G
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF
    Am J Med; 2008 Aug; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving cardiovascular health outcomes through the use of evidence-based medicine.
    Douglas J
    Ethn Dis; 2005; 15(2 Suppl 2):S23-6. PubMed ID: 15822833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
    Flaa A; Aksnes TA; Strand A; Kjeldsen SE
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive therapy in patients with metabolic syndrome.
    Segura J; Ruilope LM
    Curr Opin Nephrol Hypertens; 2006 Sep; 15(5):493-7. PubMed ID: 16914961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of blood pressure control in the patient with diabetes.
    Bakris GL
    Am J Med; 2004 Mar; 116 Suppl 5A():30S-38S. PubMed ID: 15019861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive medications and risk of diabetes mellitus.
    Barzilay JI; Cutler JA; Davis BR
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):256-60. PubMed ID: 17420670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension and renal disease].
    Kamper AL; Pedersen EB; Strandgaard S
    Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and the kidney.
    Wiederkehr M; Toto R; Fenves AZ; Ram CV
    Semin Nephrol; 2005 Jul; 25(4):236-45. PubMed ID: 16202696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons in hypertension from new clinical trials.
    Nesbitt SD
    Postgrad Med; 2009 Nov; 121(6):34-43. PubMed ID: 19940415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"].
    Tislér A
    Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.